Evidence map›Paper›PMID 18171924›Full record

ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience2008

The role of hippocampal GluR1 and GluR2 receptors in manic-like behavior.

Jing Du, Thomas K Creson, Long-Jun Wu, Ming Ren, Neil A Gray, Cynthia Falke, Yanling Wei, Yun Wang, Rayah Blumenthal, Rodrigo Machado-Vieira and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 1 pooled it
5.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 1 synthesis or guideline pooled it, 107 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Pharmacogenomics of Lithium Response in Bipolar Disorder.Pharmaceuticals (Basel, Switzerland) · 2021
    Review
  6. PKN1 Is a Novel Regulator of Hippocampal GluA1 Levels.Frontiers in synaptic neuroscience · 2021
    Article
  7. Behavioral Deficits in Mice with Postnatal Disruption ofCerebral cortex communications · 2021
    Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Jing DuLaboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20878, USA.
Thomas K Creson
Long-Jun Wu
Ming Ren
Neil A Gray
Cynthia Falke
Yanling Wei
Yun Wang
Rayah Blumenthal
Rodrigo Machado-Vieira
Peixiong Yuan
Guang Chen
Min Zhuo
Husseini K Manji
National Institutes of Health · USUniversity of Toronto · CANational Institute of Mental Health · US

Funding

AMPA receptor trafficking in the pathophysiology and treatment of mood disordersZ01MH002831 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI MANJI, HUSSEINI K · 2003 to 2008
$812k
AMPA receptor trafficking in the pathophysiology and treatment of mood disordersZIAMH002831 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI HERKENHAM, MILES A. · 2009 to 2010
$534k
Intramural NIH HHS Z01 MH002831
6 · The paper itself

Abstract

The cellular basis underlying the complex clinical symptomatology of bipolar disorder and the mechanisms underlying the actions of its effective treatments have not yet been fully elucidated. This study investigated the role of hippocampal synaptic AMPA receptors. We found that chronic administration of the antimanic agents lithium and valproate (VPA) reduced synaptic AMPA receptor GluR1/2 in hippocampal neurons in vitro and in vivo. Electrophysiological studies confirmed that the AMPA/NMDA ratio was reduced in CA1 regions of hippocampal slices from lithium-treated animals. Reduction in GluR1 phosphorylation at its cAMP-dependent protein kinase A site by the synthetic peptide TAT-S845, which mimics the effects of lithium or VPA, was sufficient to attenuate surface and synaptic GluR1/2 levels in hippocampal neurons in vitro and in vivo. Intrahippocampal infusion studies with the AMPA-specific inhibitor GYKI 52466 [4-(8-methyl-9H-1,3-dioxolo[4,5-h][2,3]benzodiazepin-5-yl)-benzenamine hydrochloride], a GluR1-specific TAT-S845 peptide, showed that GluR1/2 was essential for the development of manic/hedonic-like behaviors such as amphetamine-induced hyperactivity. These studies provide novel insights into the role of hippocampal GluR1/2 receptors in mediating facets of the manic syndrome and offer avenues for the development of novel therapeutics for these disorders.

Indexed as

AnimalsAntimanic AgentsBehavior, AnimalBenzodiazepinesBipolar DisorderCells, CulturedDisease Models, AnimalEmbryo, MammalianExcitatory Amino Acid AntagonistsExploratory BehaviorHippocampusIn Vitro TechniquesMaleMiceMice, Inbred C57BLNeuronsAntimanic AgentsBenzodiazepinesExcitatory Amino Acid Antagonistsglutamate receptor ionotropic, AMPA 2GYKI 52466Receptors, AMPAValproic Acid

Identifiers

PMID18171924
PMCPMC2763546
OpenAlexW2094730014

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.